Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Physical Characterization and Stabilization of a Lentiviral Vector Against Adsorption and Freeze-Thaw.

Kumru OS, Wang Y, Gombotz CWR, Kelley-Clarke B, Cieplak W, Kim T, Joshi SB, Volkin DB.

J Pharm Sci. 2018 Nov;107(11):2764-2774. doi: 10.1016/j.xphs.2018.07.010. Epub 2018 Jul 12.

PMID:
30017889
2.

Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.

Stoddart CA, Galkina SA, Joshi P, Kosikova G, Long BR, Maidji E, Moreno ME, Rivera JM, Sanford UR, Sloan B, Cieplak W, Wrin T, Chan-Hui PY.

Virology. 2014 Aug;462-463:115-25. doi: 10.1016/j.virol.2014.05.036. Epub 2014 Jun 25.

3.

Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Grandea AG 3rd, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, Mitcham JL, Cieplak W, Stewart SM, Grantham ML, Pekosz A, Kiso M, Shinya K, Hatta M, Kawaoka Y, Moyle M.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12658-63. doi: 10.1073/pnas.0911806107. Epub 2010 Jul 1.

4.

ARF binds the C-terminal region of the Escherichia coli heat-labile toxin (LTA1) and competes for the binding of LTA2.

Zhu X, Kim E, Boman AL, Hodel A, Cieplak W, Kahn RA.

Biochemistry. 2001 Apr 17;40(15):4560-8.

PMID:
11294623
5.

Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant.

Ulrich JT, Cieplak W, Paczkowski NJ, Taylor SM, Sanderson SD.

J Immunol. 2000 May 15;164(10):5492-8.

6.

Effectors increase the affinity of ADP-ribosylation factor for GTP to increase binding.

Zhu X, Boman AL, Kuai J, Cieplak W, Kahn RA.

J Biol Chem. 2000 May 5;275(18):13465-75.

8.

Female protein, amyloidosis, and hormonal carcinogenesis in Turkish hamster: differences from Syrian hamster.

Coe JE, Cieplak W, Hadlow WJ, Ross MJ.

Am J Physiol. 1997 Sep;273(3 Pt 2):R934-41.

PMID:
9321870
9.

Identification and molecular cloning of a gene encoding a fibronectin-binding protein (CadF) from Campylobacter jejuni.

Konkel ME, Garvis SG, Tipton SL, Anderson DE Jr, Cieplak W Jr.

Mol Microbiol. 1997 Jun;24(5):953-63.

12.

Role of a potential endoplasmic reticulum retention sequence (RDEL) and the Golgi complex in the cytotonic activity of Escherichia coli heat-labile enterotoxin.

Cieplak W Jr, Messer RJ, Konkel ME, Grant CC.

Mol Microbiol. 1995 May;16(4):789-800. Erratum in: Mol Microbiol 1996 Feb;19(3):650.

PMID:
7476173
14.

Identification and characterization of an intervening sequence within the 23S ribosomal RNA genes of Campylobacter jejuni.

Konkel ME, Marconi RT, Mead DJ, Cieplak W Jr.

Mol Microbiol. 1994 Oct;14(2):235-41.

PMID:
7530317
15.

Cloning and expression of the hup encoding a histone-like protein of Campylobacter jejuni.

Konkel ME, Marconi RT, Mead DJ, Cieplak W Jr.

Gene. 1994 Aug 19;146(1):83-6.

PMID:
8063109
16.

Nucleotide sequence and analysis of the gene in Borrelia burgdorferi encoding the immunogenic P39 antigen.

Simpson WJ, Cieplak W, Schrumpf ME, Barbour AG, Schwan TG.

FEMS Microbiol Lett. 1994 Jun 15;119(3):381-7.

PMID:
8050720
17.

Homology between Borrelia burgdorferi OspC and members of the family of Borrelia hermsii variable major proteins.

Margolis N, Hogan D, Cieplak W Jr, Schwan TG, Rosa PA.

Gene. 1994 May 27;143(1):105-10.

PMID:
8200524
18.

Recombinant microbial ADP-ribosylating toxins of Bordetella pertussis, Vibrio cholerae, and enterotoxigenic Escherichia coli: structure, function, and toxoid vaccine development.

Burnette WN, Cieplak W Jr, Kaslow HR, Rappuoli R, Tuomanen EI.

Bioprocess Technol. 1994;19:185-203. Review. No abstract available.

PMID:
7764758
19.
20.
22.

Characteristics of the internalization and intracellular survival of Campylobacter jejuni in human epithelial cell cultures.

Konkel ME, Hayes SF, Joens LA, Cieplak W Jr.

Microb Pathog. 1992 Nov;13(5):357-70.

PMID:
1297914
23.

Translocation of Campylobacter jejuni across human polarized epithelial cell monolayer cultures.

Konkel ME, Mead DJ, Hayes SF, Cieplak W Jr.

J Infect Dis. 1992 Aug;166(2):308-15.

PMID:
1634802
24.

Factors that influence the interaction of Campylobacter jejuni with cultured mammalian cells.

Konkel ME, Corwin MD, Joens LA, Cieplak W.

J Med Microbiol. 1992 Jul;37(1):30-7.

PMID:
1625313
25.

Group B streptococcal opacity variants.

Pincus SH, Cole RL, Wessels MR, Corwin MD, Kamanga-Sollo E, Hayes SF, Cieplak W Jr, Swanson J.

J Bacteriol. 1992 Jun;174(11):3739-49.

29.

The molecular engineering of pertussis toxoid.

Burnette WN, Mar VL, Bartley TD, Kaslow HR, Cieplak W Jr, Keith JM, Sato H, Burns DL, Arciniega JL, Shahin RD, et al.

Dev Biol Stand. 1991;73:75-8. Review.

PMID:
1778336
30.

Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen.

Kimura A, Mountzouros KT, Schad PA, Cieplak W, Cowell JL.

Infect Immun. 1990 Oct;58(10):3337-47.

31.

Photolabelling of mutant forms of the S1 subunit of pertussis toxin with NAD+.

Cieplak W Jr, Locht C, Mar VL, Burnette WN, Keith JM.

Biochem J. 1990 Jun 15;268(3):547-51.

32.
33.

Effects of mutations on enzyme activity and immunoreactivity of the S1 subunit of pertussis toxin.

Lobet Y, Cieplak W Jr, Smith SG, Keith JM.

Infect Immun. 1989 Nov;57(11):3660-2.

34.

Frame-shift mutation in the lacZ gene of certain commercially available pUC18 plasmids.

Lobet Y, Peacock MG, Cieplak W Jr.

Nucleic Acids Res. 1989 Jun 26;17(12):4897. No abstract available.

35.

Developments toward a recombinant pertussis vaccine.

Burnette WN, Whiteley DW, Mar VL, Burns DL, Kaslow HR, Cieplak W, Keith JM, Bartley TD.

Adv Exp Med Biol. 1989;251:1-7. Review. No abstract available.

PMID:
2692423
36.

Specific cleavage of diphtheria toxin by human urokinase.

Cieplak W, Hasemann C, Eidels L.

Biochem Biophys Res Commun. 1988 Dec 15;157(2):747-54.

PMID:
3144277
37.

Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope.

Burnette WN, Cieplak W, Mar VL, Kaljot KT, Sato H, Keith JM.

Science. 1988 Oct 7;242(4875):72-4.

PMID:
2459776
38.

Identification of a region in the S1 subunit of pertussis toxin that is required for enzymatic activity and that contributes to the formation of a neutralizing antigenic determinant.

Cieplak W, Burnette WN, Mar VL, Kaljot KT, Morris CF, Chen KK, Sato H, Keith JM.

Proc Natl Acad Sci U S A. 1988 Jul;85(13):4667-71.

39.

Activities of complete and truncated forms of pertussis toxin subunits S1 and S2 synthesized by Escherichia coli.

Locht C, Cieplak W, Marchitto KS, Sato H, Keith JM.

Infect Immun. 1987 Nov;55(11):2546-53.

40.
41.
42.

Characterization of plasminogen activator from two human renal carcinoma cell lines.

Nelson NF, Cieplak W, Dacus SC, Prager MD.

J Cell Physiol. 1986 Mar;126(3):435-43.

PMID:
2419348
43.
44.

Formation of stable complexes between urokinase and a human urinary component.

Cieplak W, Hart DA.

Thromb Haemost. 1985 Feb 18;53(1):36-41.

PMID:
4039474
45.

Increased plasma proteinase activity of mice bearing the BCL1 leukemia.

Hart DA, Cieplak W, Muirhead M.

Haemostasis. 1985;15(2):134-43.

PMID:
3891542
46.

Identification of subpopulations of human urinary plasminogen activators.

Hart DA, Kramer R, Cieplak W.

Thromb Haemost. 1984 Apr 30;51(2):212-6.

PMID:
6539958

Supplemental Content

Loading ...
Support Center